Acute lymphoblastic leukemia
MONDO:0004967Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.
Also known as: lymphoblastic leukaemia, lymphoblastic leukemia, ALL, ALL - acute lymphocytic leukaemia, ALL - acute lymphocytic leukemia, acute lymphoblastic leukaemia (ALL), acute lymphoblastic leukaemia (disease), acute lymphoblastic leukemia
3073 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 499 trials in this tab.
-
Can a Two-Step stem cell transplant tame Graft-Versus-Host disease?
⭐️ CURE ⭐️ CompletedThis phase 2 trial tests a two-step approach to stem cell transplantation for people with blood cancers. The method separates the infusion of donor lymphocytes from stem cells, aiming to better control the dose and reduce the risk of graft-versus-host disease, a serious complicat…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Can a cancer vaccine train the body to fight advanced tumors?
⭐️ CURE ⭐️ CompletedThis phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…
Phase: PHASE1 • Sponsor: Aston Sci. Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Custom-Made cancer vaccine tested in 25 patients
⭐️ VACCINE ⭐️ CompletedThis study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.
Phase: PHASE1 • Sponsor: Aaron Miller • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Does the pfizer vaccine work as well in immunosuppressed people? new study aims to find out
⭐️ VACCINE ⭐️ CompletedThis study looked at how well the Pfizer mRNA vaccine triggers an immune response in people with weakened immune systems compared to healthy individuals. About 539 adults received two doses of the vaccine, and researchers measured antibody levels and side effects. The goal was to…
Phase: PHASE4 • Sponsor: Karolinska University Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:01 UTC
-
Triple immunotherapy cocktail shows promise in tough cancers
Disease control CompletedThis study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could s…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 18, 2026 12:00 UTC
-
Immune cells supercharged to fight cancer: early trial shows promise
Disease control CompletedThis early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Aug 18, 2026 12:00 UTC
-
Experimental drug combo takes on tough cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
Disease control CompletedThis trial is testing whether a chemotherapy drug called treosulfan, given in different doses along with fludarabine, can safely prepare patients with advanced blood cancers for a stem cell transplant. The study focuses on patients who are not eligible for the standard, more inte…
Phase: PHASE1, PHASE2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo takes on Hard-to-Treat cancers in first human test
Disease control CompletedThis early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered donor cells take aim at returning blood cancers
Disease control CompletedThis early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a modified herpes virus turn the tide against advanced cancer?
Disease control CompletedThis early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…
Phase: PHASE1, PHASE2 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug tame advanced solid tumors?
Disease control CompletedThis early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…
Phase: PHASE1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill targets tough cancers in early human trial
Disease control CompletedThis early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…
Phase: PHASE1, PHASE2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug SKB410 enters human testing for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a targeted drug boost stem cell transplant success in lymphoma?
Disease control CompletedThis trial tests whether adding the targeted drug venetoclax to standard BEAM chemotherapy before an autologous stem cell transplant can improve outcomes for people with relapsed or refractory Non-Hodgkin lymphoma. Venetoclax works by blocking a protein that helps cancer cells su…
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a smart drug missile tame Hard-to-Treat leukemia?
Disease control CompletedThis trial is investigating whether a targeted drug called CMC-544 (inotuzumab ozogamicin), given alone or later combined with rituximab, can control acute lymphoblastic leukemia (ALL) that has returned or not responded to standard treatment. The study enrolls adults and older ch…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Major study finds safer way to give key leukemia drug to kids
Disease control CompletedThis study looked at 800 children with acute lymphoblastic leukemia to compare two forms of the drug asparaginase: a pegylated version given through a vein and a standard version given as a shot. The goal was to see which caused fewer serious side effects like allergic reactions,…
Phase: PHASE3 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can an RNAi drug shrink Hard-to-Treat tumors?
Disease control CompletedThis phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…
Phase: PHASE1 • Sponsor: Sirnaomics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase: PHASE1, PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a diet and exercise program help childhood leukemia survivors live healthier?
Disease control CompletedThis trial tests whether a personalized diet and exercise program, delivered by phone and online, can help adult survivors of childhood leukemia who are overweight or obese lose weight. Participants are randomly assigned to either the active coaching program or a self-directed ap…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
A smartphone app may help young cancer survivors get fitter — a trial puts it to the test
Disease control CompletedThis phase 3 trial tests whether a web-based physical activity program, including a wearable tracker and interactive app, can improve fitness and long-term health in children and adolescents who have completed cancer treatment. Participants are randomly assigned to receive either…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a pill tame a common blood cancer in the real world?
Disease control CompletedThis study follows about 269 people with chronic lymphocytic leukemia (CLL) who are starting venetoclax, a targeted pill. Researchers will track how well the drug shrinks or controls the cancer over the first year, and how long it takes before patients need another treatment. The…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new infusion drug tame advanced solid tumors?
Disease control CompletedThis early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…
Phase: PHASE1 • Sponsor: Beijing StarMab Biomed Technology Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat leukemia
Disease control CompletedThis study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had a specific high-risk genetic change (deletion 17p). Some participants had already tried other treatments, while others were newly diagnos…
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Diabetes drug metformin tested as possible CLL treatment
Disease control CompletedThis phase 2 pilot study tested the diabetes drug metformin in 37 people with chronic lymphocytic leukemia (CLL) that had come back after treatment, or in untreated CLL with a specific genetic change (11q deletion). The goal was to see if metformin could slow the cancer's growth.…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental drug JS015 takes first steps against advanced solid tumors
Disease control CompletedThis early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tu…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New stem cell transplant approach shows promise for blood cancer patients without full matches
Disease control CompletedThis Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…
Phase: PHASE3 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug SHR-7367 takes first step against advanced cancers
Disease control CompletedThis early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …
Phase: PHASE1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental pill takes on advanced cancers alongside immunotherapy
Disease control CompletedThis early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New antibody drug takes on Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo takes on advanced cancers in first human trial
Disease control CompletedThis early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…
Phase: PHASE1, PHASE2 • Sponsor: Anaveon AG • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Boosting the immune system after transplant: could 'Killer' cells prevent relapse?
Disease control CompletedThis study tests whether giving patients their own specially grown immune cells (called cytokine-induced killer cells) shortly after a stem cell transplant is safe. The trial enrolls adults with lymphoma who are receiving a transplant of their own stem cells. Researchers will mon…
Phase: NA • Sponsor: LucasBio • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can radiation reignite cancer control after immunotherapy fails?
Disease control CompletedThis phase II trial tests whether radiation therapy can help control cancer that has spread or grown after immunotherapy. About 230 patients with metastatic or lymphoid cancers will receive targeted radiation to see if it stabilizes the disease or shrinks tumors. The study also m…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers in japanese patients
Disease control CompletedThis study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers (like leukemia and lymphoma). The goal is to see if it is safe and helps control the cancer. Participants take the drug daily, and researchers monitor side effects and how well the …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy blinatumomab shows promise in kids with relapsed leukemia
Disease control CompletedThis Phase 3 trial tested the drug blinatumomab in 111 children with high-risk relapsed B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is an immunotherapy that helps the body's immune cells attack cancer cells. The study compared blinatumomab to standard chemotherap…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
Disease control CompletedThis large phase 3 trial studied nearly 1,900 children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Researchers compared different chemotherapy combinations, including varying doses of methotrexate and adding the drug…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted therapy combo aims to improve survival in older leukemia patients
Disease control CompletedThis study tests whether adding the targeted drug inotuzumab ozogamicin to a milder chemotherapy regimen improves survival in adults over 55 with a specific type of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-negative and CD22-positive. Participants receive…
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered stem cells aim to speed recovery in blood cancer patients
Disease control CompletedThis trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard tra…
Phase: PHASE3 • Sponsor: Gamida Cell ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug RAD001 tested for tough leukemias and lymphomas
Disease control CompletedThis study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase: PHASE1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data suggests asciminib may help some leukemia patients
Disease control CompletedThis study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within th…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo shows promise for tough leukemia cases
Disease control CompletedThis phase 2 trial tested a combination of two drugs, ibrutinib and blinatumomab, in 19 adults with B-cell acute lymphoblastic leukemia that had come back or wasn't responding to treatment. The goal was to see how many patients achieved complete remission. The study is completed,…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can antibody infusions shield CLL patients from deadly infections?
Disease control CompletedThis study tested whether regular infusions of Panzyga (a concentrated antibody solution from donated blood) could prevent serious infections in people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. The trial included 247 adults with CLL who were recei…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Immune cell infusion shows promise against post-transplant blood cancer relapse
Disease control CompletedThis early-phase study tested whether specially grown immune cells (cytokine-induced killer cells) could safely treat blood cancers that return after a stem cell transplant. 21 adults with relapsed multiple myeloma or other blood cancers received these donor cells. The goal was t…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
One cord blood unit may replace two in stem cell transplants for blood cancer
Disease control CompletedThis study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Intense Pre-Transplant combo shows promise for tough leukemias
Disease control CompletedThis phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Protein and exercise combo tested to fight muscle loss in sick kids
Disease control CompletedThis pilot study tested whether giving critically ill children on breathing machines extra protein along with a personalized exercise program could help preserve muscle mass and improve recovery. The trial enrolled 18 children in the ICU and measured how feasible and safe the app…
Phase: NA • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Massive trial seeks best chemo cocktail for kids with leukemia
Disease control CompletedThis large phase 3 trial enrolled over 9,000 children with newly diagnosed standard-risk B-ALL or localized B-LLy. Researchers tested different combinations and doses of chemotherapy drugs to see which worked best with the fewest side effects. The goal was to improve disease-free…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo may make cord blood transplants safer for blood cancer patients
Disease control CompletedThis study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase: PHASE1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Early trial checks safety of blinatumomab in japanese leukemia patients
Disease control CompletedThis early-phase study tested the safety of the drug blinatumomab (Blincyto®) in 6 Japanese adults newly diagnosed with a type of leukemia called B-ALL. The main goal was to see what side effects occurred. Researchers also looked at how the drug moves through the body and whether…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Calquence capsules pass Real-World safety check in CLL patients
Disease control CompletedThis completed study looked at the safety of Calquence (acalabrutinib) capsules in 67 people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Researchers tracked side effects like infections and bone marrow problems during everyday use. …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase: PHASE1, PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can a simple drink help blood cancer patients recover from stem cell transplants?
Disease control CompletedThis study tested whether a special oral nutritional supplement (Ensure Complete) could help patients with blood cancer maintain weight and gut health after a stem cell transplant. One hundred participants were randomly assigned to receive either the supplement or a standard hosp…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental drug combo targets tough blood cancers
Disease control CompletedThis early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New radiation technique aims to safely prepare blood cancer patients for transplant
Disease control CompletedThis study tested a new way to deliver total body radiation to adults with blood cancers who need a stem cell transplant. The goal was to see if this method could effectively target cancer while protecting the lungs. 36 patients took part, and the study focused on safety and how …
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a gout drug protect kidneys in cancer patients?
Disease control CompletedThis study tested pegloticase, a drug used for gout, in 10 cancer patients with high uric acid from tumor lysis syndrome. The goal was to see if it could quickly lower uric acid levels and protect kidney function. It was a small pilot trial to gather early data.
Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New study checks bleeding risk when CLL drug meets blood thinners
Disease control CompletedThis study observed 45 people with chronic lymphocytic leukemia (CLL) who were taking the drug acalabrutinib (Calquence) along with a direct oral anticoagulant (DOAC), a type of blood thinner. The main goal was to see how many patients had serious bleeding events while on this co…
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Stem cell transplant study seeks best way to prevent immune attack
Disease control CompletedThis study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for young leukemia patients: combination chemo shows promise
Disease control CompletedThis study tested a combination of chemotherapy drugs in 318 adolescents and young adults (ages not specified but typically 15-39) with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see how well the treatment worked at killing cancer cells and stopping the d…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo shows promise for rare blood cancer
Disease control CompletedThis completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …
Phase: PHASE2 • Sponsor: Won Seog Kim • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells show promise against tough childhood cancers
Disease control CompletedThis phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo aims to tame hairy cell leukemia with fewer side effects
Disease control CompletedThis study tested a combination of two drugs—vemurafenib (taken by mouth) and rituximab (given by IV)—in 15 people with hairy cell leukemia, a rare blood cancer. The goal was to see if this treatment works as well as or better than standard chemotherapy, but with fewer side effec…
Phase: PHASE2 • Sponsor: Scripps Health • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with hard-to-treat leukemia: experimental combo shows promise
Disease control CompletedThis study tested a new combination of chemotherapy drugs for children and young adults with acute lymphoblastic leukemia (ALL) that had returned or not responded to first treatment. The goal was to find the safest dose of clofarabine when given with other medicines. Twenty parti…
Phase: PHASE1 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a lung drug stop transplant rejection? new trial tests Alpha-1 antitrypsin for GVHD
Disease control CompletedThis study tested whether a drug called alpha-1 antitrypsin (AAT) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. The trial enrolled 222 participants and compa…
Phase: PHASE2, PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could vitamin d help fight blood cancer?
Disease control CompletedThis study looked at whether giving vitamin D supplements to people with low vitamin D levels and newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia could improve their outcomes. About 197 participants received either a low or high dose of vitamin D while underg…
Phase: NA • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immune booster after transplant shows promise for blood cancer patients
Disease control CompletedThis early-phase study tested whether giving specially selected donor immune cells (NK cells) soon after a stem cell transplant is safe for people with blood cancers. Seventeen patients received the cells, and researchers monitored for serious side effects within 30 days. The goa…
Phase: PHASE1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise in preventing Graft-Versus-Host disease
Disease control CompletedThis early study tested the drug belimumab (Benlysta) to see if it could prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. GvHD is a serious condition where the donor's immune cells attack the patient's body. The main g…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug combo tested for tough childhood leukemia
Disease control CompletedThis early-phase study tested whether adding the targeted drug palbociclib to standard chemotherapy is safe for children with acute lymphoblastic leukemia that has returned or not responded to treatment. Only 2 children took part, and the main goal was to find the highest tolerab…
Phase: PHASE1 • Sponsor: Tanja Andrea Gruber • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase: PHASE1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a platelet booster keep chemo on track for lymphoma patients?
Disease control CompletedThis phase 2 study tested whether the drug romiplostim can prevent severe low platelet counts caused by chemotherapy in people with lymphoma. Eleven adult patients received weekly injections of romiplostim during their 21-day chemo cycles. The goal was to see if it could reduce t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take on childhood leukemia and lymphoma in landmark trial
Disease control CompletedThis study tested a treatment called KTE-X19, a type of CAR T-cell therapy, in 95 children and adolescents whose B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) had returned or stopped responding to standard treatments. The therapy involves collecti…
Phase: PHASE1, PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New antibiotic cocktail aims to beat infections in cancer patients
Disease control CompletedThis phase II trial tested whether a newer antibiotic combination (imipenem-relebactam) works better than standard antibiotics for treating fever caused by low white blood cell counts in cancer patients. About 100 adults with cancer or who had a stem cell transplant took part. Th…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Personalized plans boost survival odds for older stem cell patients
Disease control CompletedThis study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Dietary change may curb recurrent c. diff in cancer patients
Disease control CompletedThis study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThis early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New cocktail aims to tackle tough myeloma cases
Disease control CompletedThis study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well…
Phase: PHASE1, PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Blood cancer drug safety checked in small Follow-Up study
Disease control CompletedThis study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control CompletedThis study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Stem cell hope for leukemia patients
Disease control CompletedThis study looked at whether a stem cell transplant can help people under 65 with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. 241 participants received either standard treatment or a transplant. The main goal was to see how long th…
Phase: PHASE3 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cocktail aims to wipe out CLL early
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy (FCR) plus the drug lenalidomide in 21 people with previously untreated chronic lymphocytic leukemia (CLL). The goal was to see if adding lenalidomide could help more patients achieve a complete response, meaning no signs of…
Phase: PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug plus chemo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Early trial checks safety of experimental cancer drug
Disease control CompletedThis early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Generic cancer pill matches Brand-Name drug in study
Disease control CompletedThis study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…
Phase: NA • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New radiation combo aims to boost stem cell transplant success in tough leukemia cases
Disease control CompletedThis study tested a new way to prepare patients with relapsed or hard-to-treat acute leukemia for a donor stem cell transplant. It combined a precise form of radiation therapy (IMRT) with two chemotherapy drugs (etoposide and cyclophosphamide) before the transplant. The goal was …
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New radiation technique aims to make stem cell transplants safer for leukemia patients
Disease control CompletedThis study tested a new way to give radiation before a stem cell transplant for people aged 16 to 45 with acute lymphoblastic leukemia (ALL). The goal was to see if targeting radiation only to the bone marrow and lymph nodes (called TMLI) is safe and works as well as full-body ra…
Phase: NA • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cord blood boost: new technique shows promise for tough leukemia cases
Disease control CompletedThis study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recove…
Phase: PHASE2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can kids with cancer stop antibiotics sooner? new trial investigates
Disease control CompletedThis study looked at whether children with cancer and a fever caused by low white blood cells can safely stop antibiotics earlier than usual. 55 children took part, and half stopped antibiotics once their fever was gone for 48 hours, while the other half continued until their whi…
Phase: PHASE4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo shows promise for untreated leukemia patients
Disease control CompletedThis study tested a combination of two drugs, idelalisib and ofatumumab, in 27 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received prior treatment. The goal was to see if the combo could shrink or control the cancer better than …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immunotherapy combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo shows promise for tough lymphomas
Disease control CompletedThis study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cancer drug RS-0139 tested in humans for first time
Disease control CompletedThis early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…
Phase: PHASE1 • Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One donor, two transplants: could this end lifelong Anti-Rejection drugs?
Disease control CompletedThis pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Leukemia drug shows promise in french compassionate use study
Disease control CompletedThis study looked at how well blinatumomab works and how safe it is in 92 adults with B-cell acute lymphoblastic leukemia that had come back or was not responding to treatment. Patients received the drug through a French compassionate use program. Researchers measured survival, r…
Sponsor: Group for Research in Adult Acute Lymphoblastic Leukemia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise in controlling advanced cancers
Disease control CompletedThis study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Supercharged cord blood transplant shows promise in blood cancer trial
Disease control CompletedThis Phase 3 trial tested a special cord blood product called NiCord (omidubicel) against standard cord blood transplants in 125 people with blood cancers like leukemia and lymphoma. The goal was to see if NiCord helps the body rebuild its infection-fighting cells faster. Researc…
Phase: PHASE3 • Sponsor: Gamida Cell ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy shows promise for First-Line CLL treatment
Disease control CompletedThis phase 2 trial tested a combination of bendamustine and rituximab (BR) followed by venetoclax in 42 people with untreated chronic lymphocytic leukemia (CLL). The goal was to see how many patients responded to the full 15-month treatment. Venetoclax is an oral drug that target…
Phase: PHASE2 • Sponsor: Nicole Lamanna • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control CompletedThis study tested a new drug called MK-7684A, which combines two immune-boosting medicines (pembrolizumab and vibostolimab), in 192 people with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to see…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill targets brain tumors with IDH mutations
Disease control CompletedThis early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental CAR-T therapy shows promise in small leukemia trial
Disease control CompletedThis early-phase trial tested a new CAR-T cell therapy called ThisCART19A in 10 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The main goals were to check safety and find the right dose. Researchers tracked side effects and how well the treatment…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy shows promise for aggressive leukemia
Disease control CompletedThis study tested a drug called dasatinib combined with standard chemotherapy in 30 adults newly diagnosed with a fast-growing leukemia (Ph+ ALL). The goal was to see if the combination helps people live longer and keeps the cancer away. Patients took dasatinib daily for up to 2 …
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a targeted antibody boost chemo for kids with aggressive blood cancer?
Disease control CompletedThis phase 3 trial tested whether adding 6 doses of rituximab to standard chemotherapy improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. The study enrolled 482 high-risk patients aged 6 months to 18 years. The goal was to…
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Engineered immune cells take on tough blood cancers
Disease control CompletedThis study tested a new treatment called anti-CD19 CAR-T cell therapy for adults with B-cell blood cancers that returned or didn't respond to prior treatments. The therapy uses a patient's own immune cells, modified in a lab to target and kill cancer cells. 58 adults received the…
Phase: PHASE1, PHASE2 • Sponsor: National Research Center for Hematology, Russia • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New oral drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New pill shows promise for Hard-to-Treat leukemia and lymphoma
Disease control CompletedThis phase 2 study tested an oral drug called pirtobrutinib in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma who had already received standard treatments. The goal was to see how well the drug shrank tumors and to check f…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat cancers in small early trial
Disease control CompletedThis early-phase study tested a new treatment called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The goal was to find a safe dose and see if the therapy can shrink tumors. The study is now compl…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cancer pill tested in humans for first time
Disease control CompletedThis early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…
Phase: PHASE1 • Sponsor: Godavari Biorefineries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental CAR-T therapy targets tough blood cancers in tiny early trial
Disease control CompletedThis early-phase study tested a new cell therapy called RD13-02 in just 2 people with relapsed or refractory CD7-positive blood cancers (like T-cell leukemia or lymphoma). The treatment uses specially engineered immune cells to attack cancer cells. The main goals were to check sa…
Phase: EARLY_PHASE1 • Sponsor: MEI HENG • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cocktail aims to tackle tough leukemia
Disease control CompletedThis phase II study tested a combination of three drugs—ibrutinib, fludarabine, and pembrolizumab—in 15 people with high-risk or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if the combo could produce a complete r…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered T-Cells take on blood cancers in early trial
Disease control CompletedThis early-phase study tested a new type of cell therapy for people with advanced B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL) that had returned or not responded to standard treatments. Researchers took patients' own immune cells (T-cells) and added a special…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New melphalan combo shows promise in Half-Matched transplants for blood cancer patients
Disease control CompletedThis study tested a new version of the chemotherapy drug melphalan (EVOMELA) combined with fludarabine and total body irradiation before a half-matched (haploidentical) stem cell transplant in 43 adults with blood cancers like multiple myeloma. The goal was to see if this approac…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New nanoparticle chemo shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…
Phase: PHASE1 • Sponsor: SN BioScience • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for lymphoma patients who Can't tolerate standard drugs
Disease control CompletedThis study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had bad side effects from similar drugs like ibrutinib or acalabrutinib. The main goal was to see if zanubrutinib causes…
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New antibody drug tested in patients with relapsed blood cancers
Disease control CompletedThis early-stage trial tested the safety and best dose of flotetuzumab, an antibody drug, in 13 patients with advanced blood cancers that had come back or stopped responding to treatment. The drug works by blocking cancer cell growth. The main goal was to see what side effects oc…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New drug combo shows promise for tough blood cancers in early trial
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New pill shows promise for tough blood cancers in early trial
Disease control CompletedThis early-phase study tested an experimental oral drug called LP-108, given alone or with another drug (azacitidine), in 32 adults with blood cancers (MDS, CMML, or AML) that returned or didn't respond to prior therapy. The main goals were to find the safest dose and understand …
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a targeted drug tame CLL? small trial seeks answers
Disease control CompletedThis Phase 2 trial tested the drug dasatinib in 17 people with chronic lymphocytic leukemia (CLL) who had already received other treatments. The goal was to see if dasatinib could shrink or control the cancer. Participants took the drug by mouth twice daily, and doctors checked f…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat solid tumors
Disease control CompletedThis pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Personalized dosing of Immune-Suppressing drug may improve stem cell transplant outcomes
Disease control CompletedThis phase 3 trial tested whether giving an individualized dose of antithymocyte globulin (ATG) based on a patient's own drug levels works better than a standard fixed dose. The goal was to reduce graft-versus-host disease (a serious immune reaction) and virus reactivation after …
Phase: PHASE3 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental immune therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase: PHASE1, PHASE2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control CompletedThis study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug JAB-8263 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental antibody combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New immune booster FL115 tested in patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…
Phase: PHASE1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug IBI334 tested on 28 patients with advanced cancer
Disease control CompletedThis study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase: PHASE1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Lower chemo dose may prevent transplant complications
Disease control CompletedThis study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood dis…
Phase: PHASE2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill shows promise in early trial for tough cancers
Disease control CompletedThis early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …
Phase: PHASE1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heat and immune boost: new combo tackles Hard-to-Treat cancers
Disease control CompletedThis trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…
Phase: PHASE1, PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Brushing teeth during aplasia: safe or risky?
Disease control CompletedThis study tested whether brushing teeth is safe for patients with prolonged aplasia (low blood cell counts) after intensive chemotherapy. Currently, many hospitals only allow mouthwash to avoid bleeding and infection. The trial compared brushing with an extra-soft toothbrush plu…
Phase: PHASE3 • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
BESPONSA under the microscope: korean study tracks Real-World safety
Disease control CompletedThis completed study monitored the safety and effectiveness of BESPONSA (inotuzumab ozogamicin) in 108 Korean adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug is already approved in Korea, and this post-marketing surveillance was required to …
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill JAB-3312 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental cell therapy takes on Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a new cell therapy called IOV-2001 in 7 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that had stopped responding to standard drugs. The therapy uses a patient's own immune cells, which are collected, processed,…
Phase: PHASE1 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug NB003 tested in 258 patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…
Phase: PHASE1 • Sponsor: Ningbo Newbay Technology Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug RC88 shows promise for advanced cancers in early trial
Disease control CompletedThis study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…
Phase: PHASE1 • Sponsor: Ascletis Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo tested for advanced cancers in asian patients
Disease control CompletedThis early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…
Phase: EARLY_PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Tailored combo therapy boosts leukemia fight in adults
Disease control CompletedThis study tested a personalized, intensive treatment plan for adults aged 18-55 with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. The approach used strong chemotherapy, targeted drugs like nelarabine for T-cell ALL, and risk-based stem cell trans…
Phase: PHASE3 • Sponsor: Goethe University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug E7090 tested in patients with advanced solid tumors
Disease control CompletedThis early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental combo shows promise for Tough-to-Treat leukemia
Disease control CompletedThis phase II trial tested a combination of two drugs—MOR00208 (an antibody that targets cancer cells) and lenalidomide (which boosts the immune system)—in 41 people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic leukemia (PLL). Some …
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental CLL drug cirmtuzumab tested for safety in retreatment
Disease control CompletedThis early-phase study tested the safety of cirmtuzumab, an experimental antibody that targets a protein called ROR1 found on CLL cancer cells but rarely on healthy cells. Only 3 people with CLL who had previously received cirmtuzumab were retreated for 6 to 12 months. The main g…
Phase: PHASE1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo could make blood cancer transplants safer and more available
Disease control CompletedThis study tested whether giving the drug cyclophosphamide after a stem cell transplant could help prevent a serious complication called graft-versus-host disease (GVHD) in 78 blood cancer patients. The approach aimed to make transplants from less-than-perfect donors as safe and …
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New cancer drug ABBV-155 enters first human tests
Disease control CompletedThis early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check safety and how well the drugs work together. Partic…
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody drug tested in patients with Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New cancer drug shows promise in early safety trial
Disease control CompletedThis early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New maintenance therapy shows promise in preventing T-Cell cancer relapse after transplant
Disease control CompletedThis study tested whether a low dose of the drug chidamide, given after a donor stem cell transplant, can help prevent T-cell acute lymphoblastic leukemia or T-cell lymphoma from coming back. Forty-four patients aged 14 to 70 who were at high risk of relapse took part. The main g…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
BESPONSA safety tracked in over 400 leukemia patients
Disease control CompletedThis study looked at the safety of the drug BESPONSA in 421 people with a type of blood cancer called acute lymphocytic leukemia that had come back or stopped responding to treatment. All participants received BESPONSA as prescribed by their doctor. Researchers tracked side effec…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for chinese adults with Hard-to-Treat leukemia
Disease control CompletedThis study tested a drug called inotuzumab ozogamicin in 44 Chinese adults whose acute lymphoblastic leukemia (ALL) had come back or stopped responding to treatment. The drug targets a protein called CD22 on leukemia cells to destroy them. The main goal was to see how many patien…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Venetoclax under the microscope: Real-World CLL safety data released
Disease control CompletedThis study looked at how safe and effective Venetoclax is for people with chronic lymphocytic leukemia (CLL) when used in everyday medical practice. Fourteen patients were followed to track side effects and how well the drug worked. The goal was to monitor real-world use, not to …
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug duo shows early promise against advanced cancers
Disease control CompletedThis early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…
Phase: EARLY_PHASE1 • Sponsor: Akesobio Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New chemo combo before donor transplant shows promise for leukemia patients
Disease control CompletedThis study tested adding a drug called thiotepa to the usual chemotherapy given before a donor stem cell transplant for people with leukemia. The goal was to see if this stronger mix could help more patients stay cancer-free one year after the transplant. The study included 40 ad…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Chemo-Free combo shows promise for CLL patients
Disease control CompletedThis phase 2 trial tested a chemotherapy-free combination of two drugs, obinutuzumab and ibrutinib, in 135 people with previously untreated chronic lymphocytic leukemia (CLL). The treatment was given for nine months, and then the next steps were decided based on how much leukemia…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Chemo-Free hope: new combo aims to outsmart CLL
Disease control CompletedThis phase 2 trial tested a combination of two targeted drugs, venetoclax and ibrutinib, against standard chemotherapy (FCR) in 120 fit patients with intermediate-risk chronic lymphocytic leukemia (CLL). The goal was to see if the drug combo could achieve deep remission with a fi…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goal was to find the safest dose and understand side effects. Researchers also looked at…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New cancer drug GEN1056 tested in first human trial
Disease control CompletedThis early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New targeted pill shows promise for japanese blood cancer patients
Disease control CompletedThis study tested a drug called zanubrutinib in 55 Japanese patients with B-cell blood cancers that had come back or not responded to prior treatment. The goal was to check safety and how well the drug works. Zanubrutinib is taken as a pill twice daily and targets a protein that …
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental drug pair targets tough leukemias
Disease control CompletedThis early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug BR101 enters first human tests
Disease control CompletedThis early-phase trial tested a new drug called BR101 in 15 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receiv…
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New immunotherapy combo shows promise for advanced cancers
Disease control CompletedThis study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New triple therapy shows promise for resistant cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Early trial of BDB018 combo for tough cancers wraps up with just one patient
Disease control CompletedThis early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo may make bone marrow transplants safer for blood cancer patients
Disease control CompletedThis early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy shows promise for relapsed leukemia
Disease control CompletedThis early-phase trial tested a combination of two drugs—blinatumomab and pembrolizumab—in 16 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) who had high levels of cancer cells in their bone marrow. The goal was to see if adding pembrolizumab to bl…
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise for leukemia patients with other health problems
Disease control CompletedThis Phase 3 trial tested a combination of obinutuzumab and venetoclax against obinutuzumab plus chlorambucil in 445 people with untreated chronic lymphocytic leukemia (CLL) who also had other medical conditions. The goal was to see which combo worked better at delaying disease p…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to boost immune system against tough cancers
Disease control CompletedThis early-phase trial tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug is designed to both activate immune cells and block signals that help tumors grow. The main goal was to find a safe do…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New immunotherapy DF9001 targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Tailored chemo dosing shows promise for adult leukemia
Disease control CompletedThis phase II study tested a personalized dosing approach for the chemotherapy drug L-asparaginase in 100 adults aged 18-50 with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see if adjusting doses based on individual drug levels could help more patients com…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy for CLL shows promise in small japanese study
Disease control CompletedThis completed phase 2 study tested two drug combinations—venetoclax plus obinutuzumab or venetoclax plus ibrutinib—in 20 Japanese adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how well these combinati…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antibody combo tested in advanced cancer patients
Disease control CompletedThis early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to stall lymphoma without chemo
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug copanlisib to the standard antibody rituximab helps people with relapsed indolent B-cell non-Hodgkin's lymphoma live longer without their cancer getting worse. The study included 458 adults who had already received at lea…
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antibody drug shows promise in early blood cancer trial
Disease control CompletedThis early-stage trial tested a new drug called JNJ-75348780 in 147 people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safe…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New 'Bispecific' antibody takes aim at Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a drug called odronextamab in 200 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had stopped responding to prior treatments. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to kill …
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug AMG 256 tested in patients with hard-to-treat cancers
Disease control CompletedThis early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Donor CAR-T cells take on aggressive t-cell leukemia in early trial
Disease control CompletedThis early-phase study tested a new treatment called WU-CART-007 for people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that came back or didn't respond to standard therapy. The treatment uses immune cells from a healthy donor that are specially designed to…
Phase: PHASE1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New cancer drug shows early promise in small safety trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer cocktail shows promise in early human trial
Disease control CompletedThis early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Triple-Drug cocktail shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of three drugs—selinexor, nivolumab, and ipilimumab—in 11 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of the combination, whi…
Phase: PHASE1 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental combo aims to boost stem cell transplant for rare blood cancers
Disease control CompletedThis early-phase trial tested whether adding the drug romidepsin before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Twenty-three patients received romidepsin along with standard chemotherapy, followed by a donor stem cell transpl…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 18:59 UTC
-
New combo therapy targets Hard-to-Treat tumors
Disease control CompletedThis early-phase trial tested a new drug called RiMO-301, injected directly into tumors, along with standard radiation. It involved 32 people with advanced cancers that could not be cured. The main goal was to find a safe dose and check for any early signs of tumor shrinkage.
Phase: PHASE1 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:16 UTC
-
Chemo-Free combo shows promise for older CLL patients
Disease control CompletedThis study tested a combination of two drugs, ibrutinib and obinutuzumab, in 32 older adults (65+) or those with health issues who had untreated chronic lymphocytic leukemia (CLL). The goal was to see if the combo could safely reduce cancer cells without using chemotherapy. The t…
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 26, 2026 17:04 UTC
-
New pill plus immunotherapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
Cholesterol drug shows promise in early leukemia trial
Disease control CompletedThis early-phase trial tested adding the cholesterol drug pitavastatin to the standard leukemia medicine venetoclax in 6 people with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). The main goal was to find a safe dose and check for side effects. Researchers a…
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 26, 2026 15:42 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
Smart baby gym could predict motor delays before they start
Diagnosis CompletedThis study is testing a new way to detect motor delays in infants using a special play mat with sensors and a smart toy. Researchers will watch how babies move and interact with the toy, then use AI to spot early signs of disability. The goal is to create an easy, objective tool …
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New PET tracer aims to spot hidden cancers without biopsy
Diagnosis CompletedThis completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Blood test may spot deadly transplant complication earlier
Diagnosis CompletedThis completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New imaging agent could sharpen detection of blood cancers
Diagnosis CompletedThis early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells.…
Phase: PHASE1 • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New PET tracer aims to light up hidden infections
Diagnosis CompletedThis early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New optical device aims to detect dangerous neutropenia without needles
Diagnosis CompletedThis study tested a device called PointCheck that uses light to check for severe neutropenia (low white blood cells) in cancer patients without needing a blood sample. Researchers enrolled 81 adults with blood or breast cancers who were receiving chemotherapy. The main goal was t…
Phase: NA • Sponsor: Leuko Labs, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Text reminders help get young kids vaccinated on time
Prevention CompletedThis study tested whether sending text message reminders to parents could increase routine vaccination rates in children aged 0-2 years. Over 1,000 families in Brooklyn, New York, whose children were behind on vaccines received texts when shots were due or coming due. The goal wa…
Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to stop transplant rejection
Prevention CompletedThis phase II trial tested whether giving high doses of cyclophosphamide and bortezomib after a stem cell transplant could prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Twenty-three adults with blood cancers received…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Diabetes drug shows promise in preventing deadly transplant complication
Prevention CompletedThis study tested whether sitagliptin, a diabetes medicine, could prevent acute graft-versus-host disease (GVHD) in 190 adults receiving stem cell transplants from related or unrelated donors. Participants took sitagliptin along with standard GVHD prevention. The main goal was to…
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Peppermint and lemon scents put to the test against chemo nausea
Symptom relief CompletedThis phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 18, 2026 12:00 UTC
-
Can music and mindfulness ease the toll of stem cell transplants?
Symptom relief CompletedThis study tests an electronic program that combines mindfulness and music therapy for people undergoing stem cell transplants for blood cancers. The goal is to see if it improves quality of life and reduces symptoms like pain. About 60 adults will participate, and the program in…
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Could gratitude exercises aid blood cancer recovery?
Symptom relief CompletedThis trial tests whether a phone-based positive psychology program can improve mood, quality of life, and daily functioning in adults who have just undergone a stem cell transplant for blood cancer. Participants receive weekly calls and complete exercises focused on gratitude, pe…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
Symptom relief CompletedThis trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…
Phase: NA • Sponsor: Joanne Wolfe, MD, MPH • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Virtual reality goggles could ease cancer Patients' procedure fears
Symptom relief CompletedThis study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…
Phase: NA • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
New program aims to ease lymphoma Survivors' fear of recurrence
Symptom relief CompletedThis study tests a program called UPLYFT designed to help lymphoma survivors who have finished treatment cope with the fear that their cancer might return. The program provides information and tools to improve quality of life and reduce worry. Researchers will first gather feedba…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can talking it out ease PTSD in cancer patients during a pandemic?
Symptom relief CompletedThis study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…
Phase: NA • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Could End-of-Life care for blood cancer patients be done at home?
Symptom relief CompletedThis study tests whether a hospital-at-home care model can help people with advanced blood cancers receive end-of-life care at home instead of in the hospital. Participants use remote monitoring and home-based supportive care, with researchers tracking how many enroll and complet…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Could kids have upper limb surgery fully awake? new trial tests the idea
Symptom relief CompletedThis trial tests whether a local anesthetic injection (ropivacaine) can keep children aged 6 to 12 awake and comfortable during upper limb surgery, avoiding general anesthesia. Children watch cartoons on a tablet for distraction while the anesthetic is given. The study aims to se…
Phase: PHASE4 • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Can a simple drug stop kids from waking up confused after eye surgery?
Symptom relief CompletedThis study tests whether giving sugammadex (a drug that reverses muscle relaxants) can lower the chance of children waking up agitated after strabismus (eye muscle) surgery. About 76 children aged 4 to 7 will be randomly assigned to receive either sugammadex or a standard drug (n…
Phase: PHASE4 • Sponsor: Konkuk University Medical Center • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Which exercise helps kids bounce back after leukemia? new study tests two approaches
Symptom relief CompletedThis study looked at 72 children aged 10-18 who finished chemotherapy for acute lymphoblastic leukemia. Researchers compared two types of aerobic exercise—one with a steady intensity and one that gradually increases—to see which better improves heart and lung fitness. All kids ex…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Cartoon calm: animated film may ease Kids' surgery fears
Symptom relief CompletedThis trial investigates whether a double-reading animated film, watched by both children and their parents before surgery, can reduce anxiety in children aged 3 to 7. The film uses avatars to walk the child through their hospital journey, from room to operating room. Researchers …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Acupressure may ease fatigue in young cancer survivors
Symptom relief CompletedThis study tested whether young cancer survivors (ages 15-39) could learn to do acupressure on themselves to reduce fatigue. 42 people who had finished cancer treatment at least three months ago and still felt tired took part. They used a special tool and a phone app to apply pre…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New program helps caregivers of stem cell patients cope better
Symptom relief CompletedThis study tested a support program for people caring for a loved one undergoing a stem cell transplant for blood cancer. The program included 8 online sessions over 12 weeks to teach stress management, coping skills, and communication. 17 caregivers took part, and the study chec…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Talking away the tiredness: CBT tackles Post-Transplant fatigue
Symptom relief CompletedThis study looked at whether a type of talk therapy called cognitive-behavioral therapy (CBT) can help reduce the severe tiredness that many people feel after a stem cell transplant for blood cancer. 66 adults who had a transplant at least 6 months earlier and still had significa…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Sexual health help for stem cell survivors shows promise
Symptom relief CompletedThis study tested a program to help stem cell transplant survivors who have sexual problems. Participants met with a nurse for three months and got educational materials. The goal was to see if this improved their sexual satisfaction, quality of life, and mood. The study involved…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Phone calls may boost chemo success in leukemia patients
Symptom relief CompletedThis study tested whether weekly nurse phone calls could help people with chronic lymphocytic leukemia (CLL) stick to their chemotherapy plan and reduce side effects. Sixty patients were split into two groups: one received regular care, and the other also got a weekly call to che…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Meditation may ease anxiety and improve sleep for stem cell patients
Symptom relief CompletedThis study tested whether mindfulness meditation training could help patients who are undergoing a stem cell transplant and staying in a sterile room. 70 adult patients participated, and the researchers measured their anxiety and sleep quality before and after the meditation prac…
Sponsor: Henan University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Exercise boosts recovery in stem cell patients, small trial suggests
Symptom relief CompletedThis study tested whether a supervised 8-week exercise program (strength, endurance, and flexibility) could help patients recover after an autologous stem cell transplant. Fifteen adults with blood cancers were randomly assigned to exercise or usual care. The researchers measured…
Phase: NA • Sponsor: TC Erciyes University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can virtual physio help kids with leukemia? small study tests hybrid approach
Symptom relief CompletedThis study tested whether a hybrid (in-person and online) physiotherapy program is feasible for children aged 4-17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which included tailored exercises and games. The goal was to see if families cou…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Can a phone app help cancer survivors sleep better?
Symptom relief CompletedThis study tested a mobile health (mHealth) program designed to help people who have had a stem cell transplant for blood cancer get better sleep. Researchers wanted to see if the program was easy to use and if participants liked it. About 30 survivors, caregivers, and doctors ga…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Could a common cholesterol drug protect cancer Patients' hearing?
Symptom relief CompletedThis study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…
Phase: PHASE1, PHASE2 • Sponsor: Minia University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Robotic baby seal boosts mood in hospitalized kids
Symptom relief CompletedThis study tested whether a robotic baby harp seal could help children aged 5-18 feel less anxious and more motivated during physical or occupational therapy in the hospital. Twenty-five kids used the robot during their sessions, and researchers measured their pain, anxiety, and …
Phase: NA • Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Video game magic: AR adventure cuts opioid need in young cancer patients
Symptom relief CompletedThis study tested if playing an augmented reality game called SpellBound can help children with cancer feel less pain and need fewer opioids after surgery. 29 kids aged 5-15 who had never taken opioids before took part. The game was used alongside standard care to see if it impro…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Free blood transfusions help blood cancer patients choose hospice
Symptom relief CompletedThis study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…
Phase: NA • Sponsor: Adam Olszewski • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Shea butter and niacinamide cream may ease itching for immunotherapy patients
Symptom relief CompletedThis study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…
Phase: NA • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Shocking therapy may keep cancer patients on their feet
Symptom relief CompletedThis study tested whether neuromuscular electrical stimulation (NMES) can help Veterans with blood cancers maintain physical function and reduce fatigue during stem cell transplant. 46 participants used NMES while in the hospital. The goal was to see if this approach could preven…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Asthma drug may ease cancer treatment side effects
Symptom relief CompletedThis study tested whether montelukast (Singulair), a common asthma drug, can reduce the number and severity of infusion reactions in people receiving monoclonal antibody treatments for blood disorders. Forty adults were given montelukast along with standard premedication before t…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Could a rose geranium spray soothe Chemo-Related nose pain?
Symptom relief CompletedThis study tested whether a nasal spray made from rose geranium in sesame oil can improve symptoms of nasal vestibulitis—like dryness, discomfort, bleeding, and scabbing—in cancer patients receiving chemotherapy. Over 100 participants were randomly assigned to use either the rose…
Phase: PHASE3 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Mind over marrow: ACT therapy aims to boost transplant recovery
Symptom relief CompletedThis study tested a type of talk therapy called Acceptance and Commitment Therapy (ACT) for people undergoing stem cell transplants. The goal was to help patients cope with the physical and emotional stress of the procedure, improve their physical function, and possibly shorten h…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Laser or ozone: which eases cancer mouth sores best?
Symptom relief CompletedThis study tested two treatments—laser therapy and ozone gas—to relieve painful mouth sores caused by cancer treatment. Forty adults with head and neck or blood cancers took part. Each received one treatment daily for five days. The goal was to see which therapy better reduced so…
Phase: NA • Sponsor: University of Pavia • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Magic mushroom compound tested to calm cancer anxiety
Symptom relief CompletedThis study tested whether psilocybin, a substance from certain mushrooms, given with therapy could safely reduce anxiety and depression in 55 people with metastatic cancer. Participants received counseling and a pharmaceutical-grade psilocybin dose. The trial focused on safety an…
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Can reiki ease cancer pain? small study says maybe
Symptom relief CompletedThis study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Resear…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Can acupressure calm chemo anxiety? small study investigates
Symptom relief CompletedThis pilot study tested whether acupressure, a noninvasive technique, can help reduce anxiety in patients receiving chemotherapy. Thirty adults undergoing chemo at Mayo Clinic who reported at least mild anxiety were offered a nurse-led acupressure session and taught how to do it …
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Small gestures, big impact? study tests kindness and gratitude for cancer patients
Symptom relief CompletedThis study tested whether doing simple positive activities—like performing a kind act or writing a gratitude letter—could improve quality of life for cancer patients from collectivist cultures (e.g., Latino, Asian American, African American). 75 patients and their caregivers part…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
HIIT and weights show promise for stem cell recovery
Symptom relief CompletedThis study looked at whether 12 weeks of high-intensity interval training (HIIT) and resistance training could help people who had a stem cell transplant for blood cancer. It involved 16 patients and their caregivers. The goal was to see if exercise improves physical function, th…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
New study tests monthly day care for advanced cancer patients
Symptom relief CompletedThis study looked at whether monthly visits to a hospital day care that includes palliative care can improve quality of life for adults with advanced cancer. 144 patients with a life expectancy between 2 and 12 months took part. Researchers measured changes in quality of life, fa…
Phase: NA • Sponsor: Institut Curie • Aim: Symptom relief
Last updated Jun 26, 2026 18:50 UTC
-
Empowerment program shows promise for healthier habits in young leukemia patients
Symptom relief CompletedThis study tested a child-centered empowerment program designed to help children with leukemia improve their lifestyle habits, including nutrition, sleep, physical activity, and stress management. Forty-six children aged 7-13 took part, with half receiving the program and half ge…
Phase: NA • Sponsor: Near East University, Turkey • Aim: Symptom relief
Last updated Jun 26, 2026 14:44 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 18, 2026 12:00 UTC
-
PET scans may reveal hidden leukemia spots before CAR t treatment
Knowledge-focused CompletedThis pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 12:00 UTC
-
Scientists decode cancer genes to personalize treatment
Knowledge-focused CompletedThis completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Fine-Tuning MRI scanners to sharpen the picture of the brain
Knowledge-focused CompletedThis study uses a research-dedicated 3T MRI scanner to develop and optimize imaging protocols in healthy adults. Researchers aim to reduce image distortions, improve contrast and resolution, and create new sequences for functional MRI. The work will help enable future studies in …
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
ECMO in kids with cancer: a closer look at survival and risks
Knowledge-focused CompletedThis study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Russian study to monitor Real-World use of acalabrutinib in CLL patients
Knowledge-focused CompletedThis observational study will follow about 90 adults with chronic lymphocytic leukemia (CLL) in Russia who are prescribed acalabrutinib as part of their routine care. Researchers will collect data from medical records to see how long patients stay free of disease progression and …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
New dashboard aims to make leukemia trials more inclusive
Knowledge-focused CompletedThis study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enroll…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Wearable patch and phone app could spot dangerous fevers before they spike in cancer therapy
Knowledge-focused CompletedThis study tests two devices — a wearable temperature patch and a smartphone app that measures vital signs from a facial scan — in adults with blood cancers receiving CAR-T or bispecific T-cell engager therapy. The goal is to see if these tools can detect fevers and other signs o…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
New tool could help spot brain issues in At-Risk newborns earlier
Knowledge-focused CompletedThis study is translating and testing a Turkish version of the Hammersmith Neonatal Neurological Examination (HNNE) for high-risk infants, such as premature babies or those with birth complications. Researchers will check if the exam is reliable and valid for use in Turkey by com…
Sponsor: Kahramanmaras Sutcu Imam University • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Can genes predict liver damage from childhood cancer drugs?
Knowledge-focused CompletedThis study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Researchers review CAR T-Cell results in kids with B-ALL
Knowledge-focused CompletedThis study looked back at the medical records of 57 children and young adults (under 25) who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). The goal was to understand how well the treatment worked and what side effects occurred, especially in those w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study examines artery complications in child liver transplants
Knowledge-focused CompletedThis study looked at 583 children who had liver transplants and later developed narrowing or blockage of the liver artery. Researchers wanted to find out how common these problems are and what treatments work best. The goal is to improve care and outcomes for future patients.
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gene test spots hidden leukemia in kids
Knowledge-focused CompletedThis study looked at 148 children with T-cell acute lymphoblastic leukemia to see if a high-tech gene test could find tiny amounts of cancer left after treatment. Researchers used next-generation sequencing to check for specific gene changes in immune cells. They then compared th…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Instacart and nutrition calls may ease food insecurity for cancer survivors
Knowledge-focused CompletedThis study tested whether providing grocery delivery (via Instacart) and weekly nutrition coaching calls helps cancer survivors who struggle to afford healthy food. Forty survivors who had finished active cancer treatment took part. The goal was to see if this support was practic…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New study tracks immune cell function after stem cell transplants to personalize care
Knowledge-focused CompletedThis completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New program aims to break down barriers to cancer trial participation
Knowledge-focused CompletedThis pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Mold infection risk in kids with leukemia: a 14-year review
Knowledge-focused CompletedThis study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…
Sponsor: University of Southern Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New breathing tube technique shows promise for kids in surgery
Knowledge-focused CompletedThis study looked at a different way to help children breathe during surgery. Instead of placing the breathing tube all the way into the windpipe, doctors placed it just above the vocal cords. The goal was to see if this method is easy, safe, and works well. The study included 85…
Sponsor: American University of Beirut Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Leukemia Patients' hidden threat: fungal infections under microscope
Knowledge-focused CompletedThis study observed 150 adults with a specific type of leukemia (Ph-negative ALL) to see how many developed serious fungal infections during their first weeks of chemotherapy. Researchers tracked infection rates and deaths linked to these infections. The goal was to better unders…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New drug EP395 tested in humans for first time
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of a new drug called EP395 in 78 healthy adults aged 18-65. Participants received either EP395 or a placebo capsule, and researchers monitored side effects, vital signs, and hearing. The goal was to find a safe dose range …
Phase: PHASE1 • Sponsor: EpiEndo Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can VR keep kids active and engaged after school? new study explores
Knowledge-focused CompletedThis study tested a virtual reality (VR) afterschool program for 32 children ages 9-17. The goal was to see if kids would use and enjoy the VR system, and to measure their physical activity. This was a pilot study to gather information, not to treat or cure any disease.
Phase: NA • Sponsor: University of Georgia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for hidden signs in blood cancers to personalize treatment
Knowledge-focused CompletedThis study collected blood, bone marrow, skin, and cheek cell samples from 650 adults with acute leukemia, myelodysplastic syndromes, or myeloproliferative disorders. Researchers analyzed the samples to find genetic, epigenetic, and drug sensitivity patterns that might predict ho…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New tool may help older cancer patients avoid harsh chemo side effects
Knowledge-focused CompletedThis study looked at 182 older adults with blood cancer or lung cancer to see if a special calculator could predict who would have severe side effects from chemotherapy. Researchers measured patients' fitness before and after treatment to better understand how well they could han…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Phase: NA • Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Manikin study tests best way to start CPR in kids
Knowledge-focused CompletedThis completed trial compared two ways to start CPR in a simulated child cardiac arrest: starting with chest compressions (AHA method) versus starting with rescue breaths (ERC method). Researchers used a manikin to measure how much air reached the lungs in the first minute. 28 he…
Phase: NA • Sponsor: Geneve TEAM Ambulances • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Hospital program helps older blood cancer patients plan future care
Knowledge-focused CompletedThis study tested a program to help older patients (age 60+) with blood cancers plan their future medical care while in the hospital. The program focused on completing advance directives and healthcare proxy forms. Out of 41 participants, the study found that the program was feas…
Phase: NA • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
COVID-19's hidden toll: fungal infections rise in transplant patients
Knowledge-focused CompletedThis study looked back at 60 adult blood cancer patients who had stem cell transplants and later developed a rare fungal infection called mucormycosis. Researchers compared cases before COVID-19 (2015-2020) to during the pandemic (2020-2024) to see if the virus, new tests, or new…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Can adding radiation to immunotherapy help advanced cancer patients? new study explores safety and 'Abscopal' effects
Knowledge-focused CompletedThis study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Blood markers may predict dangerous transplant complication
Knowledge-focused CompletedThis study looked at 70 patients who had a stem cell transplant for blood cancer. Researchers measured levels of complement proteins in the blood to see if they are linked to graft-versus-host disease, a common and serious side effect. The goal is to better understand how inflamm…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New program aims to ease financial burden for young cancer survivors
Knowledge-focused CompletedThis study tested a program called FinFit to help adolescent and young adult cancer survivors deal with money problems caused by their illness. Researchers interviewed 16 people from community cancer clinics to design and improve the program. The goal was to figure out the best w…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Cancer Patients' sepsis mystery: do extra antibiotics help?
Knowledge-focused CompletedThis study looked at 232 adult cancer patients with sepsis and low blood pressure to see if adding a type of antibiotic called aminoglycosides helps them recover faster. The main goal was to see how quickly their blood pressure returned to normal without needing strong blood pres…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Child cancer and birth defects: hidden genetic clues?
Knowledge-focused CompletedThis completed study collected information from nearly 1,000 children who had both cancer and developmental abnormalities like birth defects or growth issues. The goal was to find new genetic syndromes that make children more likely to develop cancer. Researchers analyzed blood a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Parents test new app to track baby eczema and gut health
Knowledge-focused CompletedThis completed study looked at how well parents of infants with early eczema and parents of healthy infants could use a mobile-friendly platform called OneBiome. The platform gives reports on the baby's gut microbiome and eating patterns. Researchers wanted to see if parents foun…
Sponsor: Danone Asia Pacific Holdings Pte, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
HIV Patients' CAR T-Cell cancer treatment under the microscope
Knowledge-focused CompletedThis study looked back at 30 people with HIV who received a special cancer treatment called CAR T-cell therapy for certain blood cancers. Researchers collected information from medical records to see what side effects occurred and how the immune system changed over time. The goal…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug interaction study: will antibiotics or antifungals change its effects?
Knowledge-focused CompletedThis study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Carbon fiber braces could ease ankle strain, early study suggests
Knowledge-focused CompletedThis study tested custom carbon fiber ankle braces in 9 healthy adults to see how they change forces across the ankle joint. Researchers varied the brace design and used a computer model to estimate joint contact stress. The goal was to improve the model and understand how brace …
Phase: NA • Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Leukemia Patients' clotting proteins under the microscope
Knowledge-focused CompletedThis study looked at levels of certain blood clotting proteins (antithrombin III, protein C, protein S, and D-dimer) in 60 people with acute leukemia and compared them to 30 healthy volunteers. The goal was to see if these proteins are different in leukemia patients. No treatment…
Sponsor: Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Leukemia Survivors' immunity under the microscope
Knowledge-focused CompletedThis study followed 89 children who finished chemotherapy for acute lymphoblastic leukemia (ALL) to see how their immune systems bounced back. Researchers measured antibody levels for vaccine-preventable diseases and tracked infections during the first year off treatment. The goa…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Gut health under the microscope: new study targets hidden danger in ICU blood cancer patients
Knowledge-focused CompletedThis completed study looked at how common gut inflammation and leaky gut are in 80 adults with blood cancer who were in intensive care for sepsis or septic shock. Researchers measured two markers—calprotectin in stool and zonulin in blood—to better understand intestinal dysfuncti…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Could tiny particles explain clot danger in kids with leukemia?
Knowledge-focused CompletedThis completed study looked at 24 children with acute lymphoblastic leukemia to see if tiny cell fragments called microparticles contribute to dangerous blood clots during treatment. Researchers collected blood samples to measure these particles and a clotting protein on their su…
Phase: NA • Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Cancer patients happier getting immunotherapy at home?
Knowledge-focused CompletedThis French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists try out new tools to feel how hard tumors are
Knowledge-focused CompletedThis study tested two new methods to measure pressure and stiffness inside solid tumors in 27 patients. One method uses a thin catheter to measure pressure directly, and the other uses sound waves like an ultrasound to check stiffness. The goal was to see if these measurements co…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Formula showdown: which one helps sick Kids' gut bugs?
Knowledge-focused CompletedThis study compared two types of liquid food (Pediasure and Nourish) to see how they affect the gut bacteria in 32 critically ill children ages 1-17 in the ICU. Researchers collected stool and saliva samples to track changes in the microbiome. The goal was to understand how diffe…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
New study tracks brain changes after stem cell transplants in seniors
Knowledge-focused CompletedThis study looked at how stem cell transplants affect thinking, memory, and daily activities in adults aged 60 to 85 with blood cancer. Researchers measured cognitive function, physical function, and quality of life at several points after transplant. The goal was to understand w…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Which donor search strategy saves more lives?
Knowledge-focused CompletedThis study looked at 1,753 patients needing a stem cell transplant for blood cancers or other serious blood disorders. Researchers compared two strategies: first searching for a matched unrelated donor, then trying an alternative donor if needed, versus going straight to an alter…
Phase: NA • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Antibody clues after stem cell transplants could prevent rejection
Knowledge-focused CompletedThis completed study looked at 314 people with blood cancers who received stem cell transplants from mismatched donors. Researchers tracked donor-specific antibodies after transplant to see how often they appear and what factors influence them. The goal is to better understand an…
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Swallow a thermometer? new study tests pill that takes your temperature from inside
Knowledge-focused CompletedThis study tested whether a small, swallowable capsule can accurately measure body temperature in 30 hospitalized patients with blood cancers who have very low immunity (neutropenia). Researchers compared the capsule's temperature readings to standard ear thermometer measurements…
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Do vaccines work as well in people with weak immune systems? new study investigates
Knowledge-focused CompletedThis study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutra…
Phase: PHASE4 • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can a machine read pain in silent kids?
Knowledge-focused CompletedThis study tested whether a device called the ANI monitor can measure pain in sedated children aged 2 and older in the pediatric intensive care unit. Researchers watched how the device responded during painful care and compared it to a standard behavioral pain scale. The goal was…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Question list boosts cancer Patients' confidence and reduces anxiety
Knowledge-focused CompletedThis study tested whether giving cancer patients a list of questions to ask their doctors helps them feel more empowered and less anxious. About 96 patients, along with nurses and doctors, took surveys and shared their experiences. The goal is to improve communication and make pa…
Phase: NA • Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Smart socks and activity trackers used to predict chemo side effects
Knowledge-focused CompletedThis completed study enrolled 200 cancer patients aged 40-85 who were about to start chemotherapy. Researchers tracked symptoms like numbness, daily activity, and falls using surveys, activity monitors, and even smart socks. The goal was to find simple ways for doctors to predict…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy side effects under the microscope: new study monitors autoantibodies
Knowledge-focused CompletedThis completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
CLL patients left in the dark: study maps treatment gaps after key drug fails
Knowledge-focused CompletedThis study looked at 152 adults with chronic lymphocytic leukemia (CLL) whose cancer stopped responding to a class of drugs called BTK inhibitors (like ibrutinib) and, in some cases, also to venetoclax. The goal was to understand what treatments doctors used next and how well the…
Sponsor: French Innovative Leukemia Organisation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Italian study reveals Real-World impact of targeted leukemia drug
Knowledge-focused CompletedThis study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials. The goal was to see how safe and effective the treatment was in everyday hospital use. Researchers collected informa…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
App vs. paper: which diary boosts cancer pill adherence?
Knowledge-focused CompletedThis study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Japanese CLL Patients' response to Venetoclax±Rituximab under the microscope
Knowledge-focused CompletedThis completed study in Japan looked at 89 adults with relapsed chronic lymphocytic leukemia (CLL) who took Venetoclax (with or without Rituximab) for 24 months. The main goal was to see how many had undetectable minimal residual disease (uMRD), a sign of deep response. Researche…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Heart defects may complicate recovery for childhood cancer survivors
Knowledge-focused CompletedThis completed study looked at 800 children who survived blood cancer to see if having a congenital heart defect raises their risk of death or other health problems later in life. Researchers also checked for shared genetic links between the two conditions. The goal is to better …
Sponsor: Children's Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Blood cell study aims to predict transplant complications
Knowledge-focused CompletedThis study looked at 57 people who had a stem cell transplant for blood cancer. Researchers wanted to see if certain immune cells (iNKT cells) could help predict the risk of graft-versus-host disease (GVHD), a serious side effect. They measured these cells in the blood and the tr…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New scan method could improve fungal infection care in cancer patients
Knowledge-focused CompletedThis study looked at whether a special type of scan (PET/CT) can help doctors see if treatment for a serious fungal lung infection is working earlier than usual. It involved 51 adults with blood cancer and invasive pulmonary aspergillosis. The goal was to see if the scan results …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Cancer patients with COVID: do early antiviral drugs help?
Knowledge-focused CompletedThis completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and impro…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Blood markers may predict ibrutinib success in tough leukemia
Knowledge-focused CompletedThis study followed 56 people with a high-risk form of chronic lymphocytic leukemia (CLL) who were taking the drug ibrutinib. Researchers looked for changes in the blood that could show early on whether the drug was working or failing. The goal is to find simple markers that help…
Sponsor: Oncology Institute of Southern Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Ashwagandha under the microscope: 12-Month safety check for popular herb
Knowledge-focused CompletedThis study followed 200 adults aged 18 to 65 who were already taking the herbal supplement KSM-66 ashwagandha as prescribed by their doctor. The main goal was to check for any side effects over a full year, with a focus on liver health. Researchers also looked at whether the supp…
Sponsor: SF Research Institute, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Can we predict who bounces back after a bone marrow transplant?
Knowledge-focused CompletedThis study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Gene-Based dosing study aims to make cancer drug safer
Knowledge-focused CompletedThis early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…
Phase: PHASE1 • Sponsor: Acrotech Biopharma Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New telemedicine service brings nighttime care to children in ghana
Knowledge-focused CompletedThis study tested a new service that lets parents call for medical help at night and get medicine delivered to their home for their sick children. Over 1,200 children with common illnesses like pneumonia, diarrhea, or malaria took part in three communities in Ghana. The goal was …
Phase: NA • Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC